InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,319.60
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.81%
)
Bitcoin
68,799.43
(
1.29%
)
Post# of 251933
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119689
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: CT post# 223066

Monday, 01/07/2019 3:59:31 PM

Monday, January 07, 2019 3:59:31 PM

Post# of 251933
Re: ENTA phase-2a in NASH

There are 125 patients, and the primary endpoint is ALT change from baseline. There is no post-treatment biopsy, but a pre-treatment biopsy (in addition to an elevated ALT reading and an MRI-PDFF showing ≥8% steatosis) is required to establish NASH for patients who are not diabetic or pre-diabetic.

The clinicaltrials.gov listing (https://www.clinicaltrials.gov/ct2/show/NCT03421431 ) says primary-endpoint results are expected in Mar 2019, but this date is apparently wrong, based on ENTA’s PR today.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up